FDA 483 - R.L. Fine Chem Private Limited - April 14, 2023

The FDA conducted an inspection of R.L. Fine Chem Private Limited, an API manufacturer located in Bangalore, Karnataka, India, from April 10 to April 14, 2023. The inspection resulted in the issuance of a Form FDA 483, highlighting several critical observations.

The primary violations identified include the company's failure to adequately investigate critical deviations, specifically concerning temperature and humidity excursions in stability chambers. These excursions, occurring in 2021, were not thoroughly investigated for their impact on stability samples stored under various conditions. Additionally, the firm did not adhere to its established Standard Operating Procedure (SOP) for the timely analysis of stability samples. Numerous samples were not analyzed within the required timeframe, as outlined in SOP No: QCD(R)4080, which mandates analysis within a specified period post-sample withdrawal.

These observations indicate non-compliance with regulatory expectations for maintaining quality control in stability studies, which is crucial for ensuring the safety and efficacy of pharmaceutical products. The FDA expects R.L. Fine Chem to address these issues by conducting thorough investigations into the deviations, implementing corrective actions, and ensuring adherence to established procedures.

The company is advised to discuss any objections or corrective actions with the FDA representatives or submit this information to the FDA for further review. Compliance with these regulatory requirements is essential to maintain the integrity of the manufacturing process and ensure public health safety.